Galmed Pharmaceuticals Ltd.

3.07-0.1100-3.46%Vol 278.86K1Y Perf -31.29%
Apr 16th, 2021 16:00 DELAYED
BID3.07 ASK3.11
Open3.16 Previous Close3.18
Pre-Market- After-Market3.06
 - -  -0.01 -0.33%
Target Price
16.40 
Analyst Rating
Strong Buy 1.33
Potential %
434.20 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap77.01M 
Earnings Rating
Sell
Price Range Ratio 52W %
3.30 
Earnings Date
13th May 2021

Today's Price Range

3.033.19

52W Range

2.966.29

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-8.90%
1 Month
-12.03%
3 Months
-14.48%
6 Months
-4.66%
1 Year
-31.29%
3 Years
-49.84%
5 Years
-54.32%
10 Years
-

TickerPriceChg.Chg.%
GLMD3.07-0.1100-3.46
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.40-0.48-20.00
Q03 2020-0.32-0.320.00
Q02 2020-0.31-0.2616.13
Q01 2020-0.37-0.2921.62
Q04 2019-0.37-0.39-5.41
Q03 2019-0.32-0.2134.38
Q02 2019-0.24-0.2016.67
Q01 2019-0.19-0.1710.53
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.44-7.32Negative
6/2021 QR-0.422.33Positive
12/2021 FY-1.56-4.70Negative
12/2022 FY-1.293.73Positive
Next Report Date13th May 2021
Estimated EPS Next Report-0.44
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume278.86K
Shares Outstanding25.08M
Trades Count1.03K
Dollar Volume2.10M
Avg. Volume378.85K
Avg. Weekly Volume180.04K
Avg. Monthly Volume224.49K
Avg. Quarterly Volume424.19K

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) stock closed at 3.07 per share at the end of the most recent trading day (a -3.46% change compared to the prior day closing price) with a volume of 279.10K shares and market capitalization of 77.01M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 21 people. Galmed Pharmaceuticals Ltd. CEO is Allen Baharaff.

The one-year performance of Galmed Pharmaceuticals Ltd. stock is -31.29%, while year-to-date (YTD) performance is -1.29%. GLMD stock has a five-year performance of -54.32%. Its 52-week range is between 2.96 and 6.29, which gives GLMD stock a 52-week price range ratio of 3.30%

Galmed Pharmaceuticals Ltd. currently has a PE ratio of -, a price-to-book (PB) ratio of 1.40, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -42.20%, a ROC of -43.33% and a ROE of -47.87%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Galmed Pharmaceuticals Ltd., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.44 for the next earnings report. Galmed Pharmaceuticals Ltd.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Galmed Pharmaceuticals Ltd. is Strong Buy (1.33), with a target price of $16.4, which is +434.20% compared to the current price. The earnings rating for Galmed Pharmaceuticals Ltd. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Galmed Pharmaceuticals Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Galmed Pharmaceuticals Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.67, ATR14 : 0.32, CCI20 : -143.53, Chaikin Money Flow : -0.05, MACD : -0.27, Money Flow Index : 26.50, ROC : -7.81, RSI : 31.22, STOCH (14,3) : 7.69, STOCH RSI : 0.00, UO : 39.31, Williams %R : -92.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Galmed Pharmaceuticals Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (77.78 %)
8 (88.89 %)
8 (88.89 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Hold
1 (11.11 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.11
Strong Buy
1.11

Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

CEO: Allen Baharaff

Telephone: +972 36938448

Address: 16 Tiomkin Street, Tel Aviv 6578317, , IL

Number of employees: 21

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

54%46%

Bearish Bullish

50%50%

News

Stocktwits